Erratum to: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations

Benzer Materyaller

• Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations
  Yazar:: Nattinger, Ann Butler, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Temporal Trends and Regional Variation in the Utilization of Low-Value Breast Cancer Care: Has the Choosing Wisely Campaign Made a Difference?
  Yazar:: Neuner, Joan, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• The Introduction of Generic Aromatase Inhibitors and Treatment Adherence Among Medicare D Enrollees
  Yazar:: Neuner, Joan M., ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Socioeconomic Disparities in Mortality Among Women With Incident Breast Cancer Before and After Implementation of Medicare Part D
  Yazar:: Nattinger, Ann B., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Quality of Life Among a Population-Based Cohort of Older Patients with Breast Cancer
  Yazar:: Neuner, Joan M., ve diğerleri
  Baskı/Yayın Bilgisi: (2014)